New breast cancer drug trial halted early – what we know
NCT ID NCT05954143
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with multiple therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink tumors. However, the trial was stopped early after enrolling only 11 participants, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Irvine, California, 92618, United States
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Virginia Cancer Specialists
Arlington, Virginia, 22205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer